

# NOF CORPORATION

DDS DEVELOPMENT DIVISION

YEBISU GARDEN PLACE TOWER

20-3, EBISU 4-CHOME, SHIBUYA-KU, TOKYO 150-6019 JAPAN

TEL. +81-3-5424-6741 FAX. GIII +81-3-5424-6769

<http://www.nof.co.jp/dds> E-mail: [ddsinfo@nof.co.jp](mailto:ddsinfo@nof.co.jp)



September 15, 2010

## **NOF's Activated PEG Used in an U.S. FDA Approved PEGylated Drug**

NOF supplies their activated PEG to Savient Pharmaceuticals, Inc. for their PEGylated drug KRYSTEXXA™ which has been approved by the U.S. Food and Drug Administration (FDA). NOF has an exclusive agreement with Savient for the supply of the NOF's activated PEG for Savient's PEGylated drug.

### **About Savient:**

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University (“Duke”) and Mountain View Pharmaceuticals, Inc. (“MVP”). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: <http://www.savient.com>.

### **About NOF:**

NOF CORPORATION (NOF) is a highly reputed speciality chemical manufacturer for diverse industries and fields with “From Biosphere to Outer Space”.

Based on its extensive experience with sophisticated products such as Activated phospholipids, highly purified oleic acid non-ionic surfactants and MPC polymers, NOF Drug Delivery System (DDS) Development Division has been exploiting our excellent technologies and capabilities in the pharmaceutical field complying with all of authority regulations.

### **About Activated PEG:**

NOF has been manufacturing high-purity methoxypolyethylene glycols (mPEGs) with molecular weights from 2kDa to 40kDa, and producing high-purity activated PEG derivatives of methoxy PEG amines, maleimides and carboxylic acids etc. Various alterations of the terminal ends of PEG permit drug modification as per customers' expectations and needs. Furthermore, use of PEGylated phospholipids composed of our high-purity phospholipids and PEGs allow prolongation of the plasma half-life of drugs.

KRYSTEXXA™ is a trademark of Savient Pharmaceutical, Inc. and Oxandrin® is a registered trademark of Savient Pharmaceuticals, Inc.